These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31704173)

  • 1. Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases.
    Gomes P; Leal H; Mendes AF; Reis F; Cavadas C
    Trends Pharmacol Sci; 2019 Dec; 40(12):1021-1039. PubMed ID: 31704173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirtuins as possible targets in neurodegenerative diseases.
    Donmez G
    Curr Drug Targets; 2013 Jun; 14(6):644-7. PubMed ID: 23410123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin modulators: targets for metabolic diseases and beyond.
    Szczepankiewicz BG; Ng PY
    Curr Top Med Chem; 2008; 8(17):1533-44. PubMed ID: 19075764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirtuin modulators: mechanisms and potential clinical implications.
    Sanchez-Fidalgo S; Villegas I; Sanchez-Hidalgo M; de la Lastra CA
    Curr Med Chem; 2012; 19(15):2414-41. PubMed ID: 22455589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.
    Aljada A; Dong L; Mousa SA
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1158-68. PubMed ID: 20872319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven sirtuins for seven deadly diseases of aging.
    Morris BJ
    Free Radic Biol Med; 2013 Mar; 56():133-71. PubMed ID: 23104101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurobiology of sirtuins and their role in neurodegeneration.
    Donmez G
    Trends Pharmacol Sci; 2012 Sep; 33(9):494-501. PubMed ID: 22749331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirtuins and NAD
    Kane AE; Sinclair DA
    Circ Res; 2018 Sep; 123(7):868-885. PubMed ID: 30355082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective.
    Yeong KY; Berdigaliyev N; Chang Y
    ACS Chem Neurosci; 2020 Dec; 11(24):4073-4091. PubMed ID: 33280374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
    Huber K; Superti-Furga G
    Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology, Chemistry, and Pharmacology of Sirtuins.
    Bedalov A; Chowdhury S; Simon JA
    Methods Enzymol; 2016; 574():183-211. PubMed ID: 27423863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders.
    Alageel A; Tomasi J; Tersigni C; Brietzke E; Zuckerman H; Subramaniapillai M; Lee Y; Iacobucci M; Rosenblat JD; Mansur RB; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():95-101. PubMed ID: 29802856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New assays and approaches for discovery and design of Sirtuin modulators.
    Schutkowski M; Fischer F; Roessler C; Steegborn C
    Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using mitochondrial sirtuins as drug targets: disease implications and available compounds.
    Gertz M; Steegborn C
    Cell Mol Life Sci; 2016 Aug; 73(15):2871-96. PubMed ID: 27007507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirtuin activators and inhibitors: Promises, achievements, and challenges.
    Dai H; Sinclair DA; Ellis JL; Steegborn C
    Pharmacol Ther; 2018 Aug; 188():140-154. PubMed ID: 29577959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sirtuin family's role in aging and age-associated pathologies.
    Hall JA; Dominy JE; Lee Y; Puigserver P
    J Clin Invest; 2013 Mar; 123(3):973-9. PubMed ID: 23454760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of activators and inhibitors of sirtuins.
    Balcerczyk A; Pirola L
    Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Sirtuins and Molecular Mechanisms of Aging.
    van de Ven RAH; Santos D; Haigis MC
    Trends Mol Med; 2017 Apr; 23(4):320-331. PubMed ID: 28285806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases.
    Imai S; Guarente L
    Trends Pharmacol Sci; 2010 May; 31(5):212-20. PubMed ID: 20226541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.